New stuttering drug shows promise in early trial
NCT ID NCT05583955
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called NOE-105 in 75 adult men who have stuttered since childhood. The goal was to see if it could improve speech fluency without the side effects of older treatments. Participants took the drug or a placebo for 10 weeks, and researchers measured changes in stuttering severity and daily functioning.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDHOOD-ONSET FLUENCY DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Noema Investigator site
Bellflower, California, 90706, United States
-
Noema Investigator site
Jacksonville, Florida, 32256, United States
-
Noema Investigator site
Orlando, Florida, 32801, United States
-
Noema Investigator site
Overland Park, Kansas, 66210, United States
-
Noema Investigator site
Berlin, New Jersey, 08009, United States
-
Noema Investigator site
Memphis, Tennessee, 38119, United States
-
Noema Investigator site
Brookvale, New South Wales, 2100, Australia
-
Noema Investigator site
Miranda, New South Wales, 2228, Australia
-
Noema Investigator site
Sydney, New South Wales, 2109, Australia